D. Griffin

Severe COVID-19 is associated with sustained biochemical disturbances and prolonged symptomatology; A retrospective single-centre cohort study

Z. Mitrev, M. Simjanoska, R. Rosalia, 2021, medRxiv.

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life.

S. Madajewicz, W. Tester, T. Grote, 1996, Clinical therapeutics.

Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.

R. Navari, T. Beck, M. Meshad, 1997, Cancer investigation.

Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

L. Cubeddu, J. Kish, P. Eisenberg, 1995, Clinical therapeutics.

The clinical and molecular significance associated with STING signaling in breast cancer

M. Salto‐Tellez, S. Bakhoum, R. Kennedy, 2021, npj Breast Cancer.

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life.

S. Madajewicz, W. Tester, T. Grote, 1996, Clinical therapeutics.